Risk Stratification in the Diagnosis of Cardiovascular Disease : Market Research Report

Risk Stratification in the Diagnosis of Cardiovascular Disease

Published: Sep. 29, 2005 - 18 Pages

The price of this report has been reduced due to its age. The original price was $1,900 for PDF E-mail From Publisher.

The Role of Risk Stratification: Overview—Diagnosis and Risk Stratification of Key Cardiovascular Indications; Coronary Heart Disease; Acute Coronary Syndrome; Chronic Heart Failure; Biochemical Diagnostics; Overview; Biochemical Diagnostics for CHD; Biochemical Diagnostics for ACS; Biochemical Diagnostics for CHF; The Future for Bioassays—Multi-Marker Analysis; Impact of Genetic Testing; Noninvasive Imaging Techniques; Overview; Imaging Technologies for CHD; Imaging Technologies for ACS; Imaging Technologies for CHF; Emerging Noninvasive Diagnostics—Molecular Imaging; Conclusion and Outlook
Table 1. Select Cardiovascular Disease Populations (000s) in the Major Markets, 2004 and 2009
Table 2. Point-of-Care Assays Measuring Cardiac Troponins
Table 3. Commercially Available Immunoassays for Risk Management in the Diagnosis of CHF, 2005
Figure 1. Diagnosis and Risk Assessment Decision Tree for Coronary Heart Disease
Figure 2. Diagnosis and Risk Assessment Decision Tree for Acute Coronary Syndrome
Figure 3. Diagnosis and Risk Assessment Decision Tree for Chronic Heart Failure

Abstract

The burden of cardiovascular disease continues to increase, particularly in the developed world, because of the aging demographic and the increasingly sedentary lifestyle people are adopting. The American Heart Association (AHA) estimates that the cost of cardiovascular diseases and stroke in the United States alone will be $393.5 billion in 2005. In an attempt by payers to contain costs, risk management strategies have become a central consideration during the diagnosis of key cardiovascular diseases to ensure that resources are targeted appropriately and that potentially costly sequelae are avoided. In this report, we focus on three disease areas (coronary heart disease [CHD], acute coronary syndrome [ACS], and chronic heart failure [CHF]) in which diagnostics that provide better patient risk stratification are having-and will continue to have-a significant impact. We discuss the role of currently available invasive (bioassays) and noninvasive (imaging systems) diagnostic tools with regard to risk stratification in each of these disease areas, and we provide insight as to how emerging technologies will influence future patient management.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Risk Stratification in the Diagnosis of Cardiovascular Disease

Table of Contents

Abstract